These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25397556)

  • 21. Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
    Gianotti N; Poli A; Nozza S; Galli L; Galizzi N; Ripa M; Merli M; Carbone A; Spagnuolo V; Lazzarin A; Castagna A
    BMC Infect Dis; 2017 Nov; 17(1):723. PubMed ID: 29145807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV.
    Munderi P; Were E; Avihingsanon A; Mbida PAM; Mohapi L; Moussa SB; Jansen M; Bicer C; Mohammed P; van Delft Y
    South Afr J HIV Med; 2019; 20(1):949. PubMed ID: 31392036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study.
    Falcon-Neyra L; Palladino C; Navarro Gómez ML; Soler-Palacín P; González-Tomé MI; De Ory SJ; Frick MA; Fortuny C; Noguera-Julian A; Moreno EB; Santos JL; Olbrich P; López-Cortés LF; Briz V; Neth O;
    Medicine (Baltimore); 2016 Jun; 95(24):e3842. PubMed ID: 27310962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
    Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
    HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
    Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
    J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
    Zaccarelli M; Fabbiani M; Pinnetti C; Borghi V; Giannetti A; Sterrantino G; Lorenzini P; Latini A; Loiacono L; Colafigli M; Ammassari A; D'Ettorre G; Plazzi M; Di Giambenedetto S; Antinori A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19802. PubMed ID: 25397546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Durability of single tablet regimen for patients with HIV infection in Southern Taiwan: data from a real-world setting.
    Chang HM; Chou CH; Tsai HC
    BMC Infect Dis; 2022 Jan; 22(1):2. PubMed ID: 34983388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort.
    Rokx C; Fibriani A; van de Vijver D; Verbon A; Schutten M; Gras L; Rijnders BJ
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19491. PubMed ID: 25394000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014.
    Cazanave C; Reigadas S; Mazubert C; Bellecave P; Hessamfar M; Le Marec F; Lazaro E; Peytavin G; Bruyand M; Fleury H; Dabis F; Neau D
    Open Forum Infect Dis; 2015 Jan; 2(1):ofv018. PubMed ID: 26034768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial.
    Curran A; Rull A; Navarro J; Vidal-González J; Martin-Castillo M; Burgos J; Falcó V; Ribera E; Torrella A; Planas B; Peraire J; Crespo M
    J Clin Med; 2020 Apr; 9(5):. PubMed ID: 32344934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
    Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study.
    Podzamczer D; Rozas N; Domingo P; Ocampo A; Van den Eynde E; Deig E; Vergara A; Knobel H; Pasquau J; Antela A; Crespo M; Clotet B; Muñoz J; Fernandez P; Geijo P; de Castro ER; Diz J; Casado A; Torres C
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19814. PubMed ID: 25397558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre.
    Borghetti A; Mondi A; Piccoli B; Gagliardini R; Lamonica S; Ciccarelli N; D'Avino A; Pallavicini F; Cauda R; De Luca A; Fabbiani M; Di Giambenedetto S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19817. PubMed ID: 25397561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study.
    Gazaignes S; Resche-Rigon M; Yang C; Gatey C; Munier AL; Desseaux K; Rozenbaum W; Molina JM
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19796. PubMed ID: 25397540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection.
    Bernardini C; Maggiolo F
    Patient Prefer Adherence; 2013; 7():531-42. PubMed ID: 23814462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity.
    Patterson P; Socías E; Pryluka D; Lapadula P; Pérez H; Cahn P
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19794. PubMed ID: 25397538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison.
    Taramasso L; Di Biagio A; Maggiolo F; Tavelli A; Lo Caputo S; Bonora S; Zaccarelli M; Caramello P; Costantini A; Viscoli C; d'Arminio Monforte A; Cozzi-Lepri A;
    HIV Med; 2018 May; ():. PubMed ID: 29846042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV.
    Taramasso L; Lo Caputo S; Magnasco L; Briano F; Poliseno M; Bruno SR; Ferrara S; Pincino R; Sarteschi G; Beltramini S; Sasso E; Mora S; Giacomini M; Bassetti M; Di Biagio A
    AIDS Res Hum Retroviruses; 2022 Jun; 38(6):472-479. PubMed ID: 35172617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression.
    Carbone A; Galli L; Bigoloni A; Bossolasco S; Guffanti M; Maillard M; Carini E; Salpietro S; Spagnuolo V; Gianotti N; Lazzarin A; Castagna A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19811. PubMed ID: 25397555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.